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Abstract Dendritic cells (DCs) activate and shape the
adaptive immune response by capturing antigens, migrating
to peripheral lymphoid organs where naïve T cells reside,
expressing high levels of MHC and costimulatory molecules
and secreting cytokines and chemokines. DCs are endowed
with a high degree of functional plasticity and their functions
are tightly regulated. Besides initiating adaptive immune
responses, DCs play a key role in maintaining peripheral
tolerance toward self-antigens. On the basis of the informa-
tion gathered from the tissue where they reside, DCs adjust
their functional activity to ensure that protective immunity is
favoured while unwanted or exaggerated immune responses
are prevented. A wide variety of signals from neighbouring
cells affecting DC functional activity have been described.
Here we will discuss the complex role of extracellular
nucleotides in the regulation of DC function and the role of
P2 receptors as possible tools to manipulate immune
responses.
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Abbreviations
ADP Adenosine diphosphate
ATP Adenosine triphosphate
cAMP Cyclic adenosine monophosphate
CCR Chemokine CC motif receptor
CCL Chemokine CC motif ligand
CD Cluster of differentiation
CXCL Chemokine CXC motif ligand
CXCR Chemokine CXC motif receptor
DCs Dendritic cells
IDO Indoleamine 2,3-dioxygenase
IFN Interferon
IL Interleukin
LN Lymph node
NK Natural killer
pDC Plasmacytoid dendritic cell
STAT Signal transducer and activator of transcription
TGF Transforming growth factor
Th T helper
TSP Thrombospondin
Introduction
Dendritic cells (DCs) are a heterogeneous bone marrow-
derived leukocyte population of specialised antigen-
presenting cells functioning as initiators and regulators of
T cell responses and influencing the activity of B lympho-
cytes and natural killer cells [1]. In humans, DC subsets
include interstitial DCs found in peripheral tissues, Langer-
hans cells of the skin and plasmacytoid dendritic cells
(pDCs) mostly present in the blood and in lymphoid organs.
While interstitial DCs and Langerhans cells derive from a
myeloid precursor, pDCs were initially considered of
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differentiated from either common lymphoid or common
myeloid precursors in both humans and mice. For simplicity
we will hereafter refer to interstitial DCs and Langerhans
cells as myeloid DCs. In the mouse, at least six different DC
subsets have been identified. The existence of diverse DC
populations specialised in particular tasks ensures efficient
induction of host defense to multiple pathogens and tumor
cells as well as the preservation of self-tolerance. In addition,
each DC subtype is endowed with a certain degree of
functional plasticity making the same cell able to work as a
promoter of inflammation or a regulator of immune
responses, depending on the nature of the stimulus and on
the environmental conditions in which the cell has been
activated [2]. Recent studies on the function of P2 receptors
on DCs have revealed that the presence of nucleotides (in
particular ATP) in the extracellular milieu surrounding DCs
can significantly modify DC functions.
P2 receptors
P2 receptors are a class of plasma membrane receptors
expressed by virtually all cell types. Their activation elicits
diverse responses depending on cell type, receptors ex-
pressed and nucleotide concentration. Two P2 receptor
subfamilies have been described so far and are named P2Y
and P2X. Members of the two groups differ in protein
structure, pharmacology and function [3–5].
P2Y receptors are seven membrane-spanning, G-protein-
coupled receptors whose activation triggers generation of
inositol 1,4,5-trisphosphate and release of Ca
2+ from the
intracellular stores [6]. Eight P2Y subtypes have been
cloned so far and are named P2Y1,P 2 Y 2, P2Y4, P2Y6,
P2Y11, P2Y12,P 2 Y 13, and P2Y14 [6, 7].
Neurons, heart, skeletal muscle, platelets, liver and
digestive tract express P2Y1 mRNA [6]. Stimulation of
this subtype has been linked to platelet aggregation and
nitric oxide (NO) release [8]. P2Y1 is potently activated by
ADP. The P2Y2 receptor is expressed in skeletal muscle,
heart, lung, spleen, placenta and kidney [6, 9]. Its function
has been linked to ion transport in epithelia [10]. P2Y2 is
activated with similar efficiency by ATP and UTP. P2Y4 is
present in the intestine, lung and placenta [6]. UTP is a
potent agonist at P2Y4. Expression of P2Y6 has been found
in many human tissues, including spleen, thymus, placenta,
intestine, lung and brain [6, 11, 12]. UDP is very active at
P2Y6. The P2Y11 subtype has been found in corneal
epithelia, endothelial and pancreatic duct cells, promyelo-
cytic HL-60 cells, dendritic cells and lymphocytes; its
activation is associated with increased intracellular concen-
tration of cyclic AMP [13–16]. ATP is the preferred ligand
at P2Y11 [17].
CD34
+ stem cells, mast cells, vascular smooth muscle
cells and platelets express the P2Y12 subtype [18–20]. It is
potently activated by ADP and linked to ADP-induced
shape changes in platelets [21].
P2Y13 is expressed in bone marrow, spleen, liver, brain,
airway epithelial cells, red blood cells, monocytes, dendritic
and T cells [18–20, 22, 23]. P2Y13 has recently been linked
to the regulation of hepatic high-density lipoprotein (HDL)
endocytosis [24]. Its preferred agonist is ADP [25]. The
recently identified P2Y14 subtype has been found in
hematopoietic cells, monocyte-derived dendritic cells and
human airway epithelial cells. The P2Y14 subtype responds
to UDP-glucose and related sugar nucleotides [23, 26, 27].
P2X proteins are membrane receptors that form ion
channels upon activation by extracellular ATP. Ligation of
the agonist induces oligomerization and formation of
homo—or in some cases hetero—multimer ion selective
channels, being permeable to monovalent and divalent
cations [28–30]. The P2X subunit is formed by an
extracellular loop, two transmembrane domains and two
(amino- and carboxyl-terminal) cytoplasmic domains. Sev-
en P2X subtypes have been cloned so far (P2X1, P2X2,
P2X3, P2X4,P 2 X 5, P2X6, and P2X7). They were originally
identified in mammalian neurons and smooth muscle cells,
and subsequently also found in fibroblasts, lymphocytes,
macrophages, and dendritic cells [5]. All P2X subtypes are
activated by ATP.
The P2X1 subtype is expressed by smooth muscle cells,
megakariocytes, platelets, lymphocytes, dendritic cells,
epithelial cells, ventricular myocardium, and neurons [31–
34]. 20,30-(4-benzoyl)benzoyl-ATP (BzATP) and α,β-meth-
ylene ATP are good agonists at this subtype.
P2X2 has different functional splice variants. 2meSATP
is a better agonist than ATP for this subtype. It is expressed
in pancreatic cells and neurons, where along with P2X3,i t
is involved in nociceptive responses after nerve injury [35].
P2X3 receptor is expressed by neurons and its activation
has been linked to nociceptive signaling [35, 36]; mRNA
expression of this subtype has also been found in ker-
atinocytes, and CD43
+ hematopoietic cell precursors [32].
P2X4 has been found in neurons, hematopoietic cell
precursors, macrophages, monocyte-derived dendritic cells
and fibroblasts, keratinocytes, and placenta [9, 23, 37].
P2X5 and P2X6 mRNAs have been detected in neurons,
keratinocytes and thyrocytes [38–40]. The P2X7 receptor is
expressed in macrophages, microglia, dendritic cells and
placenta [7, 9]. It is a non-desensitising receptor with the
peculiar capacity to undergo a permeability transition from
a cationic selective channel to a plasma membrane pore
upon stimulation with high or pulsed ATP doses. BzATP is
more potent than ATP at this subtype.
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Nucleotides are present at relatively high amounts in the
cytoplasm of cells where their concentration ranges from
1–10 mM. In the extracellular space their concentration is
considerably lower ranging between 1 and 10 nM. Due to
the steep concentration gradient, their small size and their
high mobility in the extracellular compartment, nucleotides
can be rapidly released along with other cellular compo-
nents following mechanical stress, cell damage or death.
Increased nucleotide concentration in the extracellular
space is therefore closely associated with tissue stress or
damage [41–43]. However non-lytic nucleotide release
may occur in many cell types under a variety of conditions.
Activated platelets represent a relevant source of ATP
released concomitantly with several inflammatory media-
tors during clot formation [43]. ATP is released from exer-
cising skeletal muscle as well as from vascular endothelial
cells and smooth muscle cells in conditions of increased
blood flow or upon mechanical stimulus [44–47]. More-
over, ATP secretion from endothelial cells and leukocytes
may be induced by pathogen-associated molecules such as
LPS [48, 49].
The ability of DCs to sense tissue stress is a cardinal
point of the danger theory [50]. In this model, rather than
be activated solely by the recognition of foreign pathogens,
DCs react to the presence of environmental molecules as-
sociated with tissue stress, the so-called danger signals.
Danger signals can be classified into endogenous and
exogenous. Endogenous danger signals can be further
subdivided into constitutive (ATP, adenosine, some heat
shock proteins) and inducible (type I interferons, some
other heat shock proteins). Exogenous danger signals
include microbial-associated molecules recognised by
Toll-like receptors expressed on a variety of cells including
DCs. The ability to recognise endogenous danger signals
allows the immune system to discriminate between harm-
less (e.g., commensal flora at mucosal surfaces) and
pathogenic organisms by assessing their effect (damage)
on the host. However, tissue damage might also be
secondary to the intrinsic toxicity of sustained inflamma-
tion, which can ultimately be as harmful as the infection
itself. In order to restore homeostasis, a timely termination
of inflammatory processes is required. Extracellular ATP, in
fact, has been suggested to be a signal of danger whose
function is to activate DCs as well as to limit excessive
inflammatory responses and promote tolerance.
Dendritic cells circulate in the bloodstream or reside in
peripheral tissues where they are specialised in the uptake
of potential antigens. In this life-cycle stage, DCs are
considered “immature” and express chemokine receptors
for inflammatory chemokines such as CXCR1, CCR1,
CCR2 and CCR5 and for other inflammatory factors
enabling them to migrate from the blood to inflamed
tissues [51–53]. Recent work by Idzko and colleagues
shows that ATP released from dying cells can be included
in the list of mediators able to recruit dendritic cells. In
vitro, exposure to low concentrations (100 nM) of extra-
cellular ATP, through the activation of P2Y receptors,
induces intracellular calcium mobilisation, actin polymeri-
sation and chemotaxis of immature, but not mature,
monocyte-derived DCs [54].
Additional evidence suggesting a role for P2Y receptors
in cell trafficking comes from the observation of mono-
cytes/macrophages from CD39-deficient mice that have
impaired ability to metabolise extracellular ATP and display
P2Y signaling pathway desensitisation associated with
reduced chemotactic responses [55]. In addition, exposure
to ATP gradients has been reported to inhibit chemokine-
elicited migration of monocyte-derived DCs and freshly
isolated CD1a
+ dermal dendritic cells but not circulating
peripheral blood CD1c
+ DCs or plasmacytoid DCs through
a P2Y11-dependent mechanism [16]. While all four DC
populations express discrete amounts of mRNA encoding
P2Y11, only monocyte-derived DCs and dermal CD1a
+
DCs display responsiveness to P2Y11 agonists, consistent
with the susceptibility to ATP gradients.
Whether circulating DCs need some unidentified signal
present in peripheral tissues (such as the skin) or in the in
vitro cultures to express functional P2Y11 protein on cell
membrane is unknown. These findings suggest a complex
role for ATP in the regulation of DC trafficking: ATP might
work as a chemoattractant for DCs toward the site of tissue
damage; on the other hand ATP gradients might prolong the
permanence of immature DCs at the site of the antigen
encounter (Figure 1).
Dendritic cells exposed to pathogen-associated mole-
cules engaging Toll-like receptors undergo maturation, a
complex process turning immature DCs into efficient
antigen-presenting cells. Additional stimuli driving DC
maturation include inflammatory cytokines such as tumor
necrosis factor alpha (TNF-α) or the engagement of CD40
by CD40 ligand expressed on activated T lymphocytes.
Early after activation, DCs produce inflammatory cyto-
kines including TNF-α, IL-1 and IL-6 and downregulate
the expression of inflammatory chemokine receptors and of
P2Y11 [16], while upregulating lymphoid chemokine
receptors CCR7 and CXCR4 [53, 56]. This sets DCs to
leave the site where activation occurred, enter into
lymphatic circulation and migrate to draining lymph nodes.
Maturing DCs progressively reduce antigen uptake
activity, while upregulating the expression of molecules
involved in antigen presentation such as major histocom-
patibility complexes (MHC) I and II, the co-stimulatory
molecules CD80 and CD86 providing signals 1 and 2 for T
cell activation. Other surface molecules involved in the
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ligand are also upregulated. In addition chemokines released
by DCs at early stages of maturation, such as CCL2, CCL3,
CCL4, CCL5, CXCL8 and CXCL10 recruit circulating
monocytes, immature DCs, Tcells and neutrophils at the site
of the antigen encounter [52, 53]. Migrating DCs upregulate
the production of lymphoid chemokines including CCL17,
CCL19 and CCL22, providing chemotactic signals for
naïve T cells and mature DCs in the lymph nodes.
Besides presenting antigens and necessary co-stimulato-
ry signals for the activation of T lymphocytes, DCs instruct
T helper cells to differentiate into IFN-γ−(Th 1 phenotype)
or IL-4-producing cells (Th 2). Th 1 differentiation is
driven by the presence of IL-12 in the microenvironment
where antigen presentation occurs [57, 58]. DCs are a major
source of IL-12, which is also an important stimulatory
factor for NK cells. Activated DCs migrating to the lymph
node induce NK recruitment through a CXCR3-dependent
mechanism [59]. DCs are a relevant source of the CXCR3
ligands CXCL9, CXCL10 and CXCL11, and both myeloid
DC and pDC supernatants have been shown to induce NK
cell migration in vitro [60]. NK trafficking into inflamed
lymph node has been proven necessary for efficient priming
of Th 1 lymphocytes in vivo [59]. In fact, IFN-γ released by
NK cells at the site of antigen presentation induces STAT-1
activation, which in turn elicits the expression of the
transcription factor t-bet in naïve T lymphocytes. Subse-
quently t-bet promotes Th 1 differentiation by driving the
expression of IL-12 receptor [61]. In this context, IL-12
produced by DCs by triggering its cognate receptor on
naïve T cells, induces STAT-4 activation, a key event for Th
1 differentiation. Conversely, the absence of IL-12 and
signals leading to t-bet expression favours Th 2 develop-
ment (Figure 2).
Immature monocyte-derived DCs exposed to chronic
stimulation with low micromolar concentrations of ATP but
not UTP undergo partial membrane maturation and upreg-
ulate CD83, CD54, CD86 as well as the lymphoid chemo-
kine receptor CCR7 conferring functional responsiveness to
lymphoid chemokines such as CCL19 and CXCL12 [56,
62]. Dendritic cells stimulated with ATP alone fail to
produce detectable cytokines [62]. However, when DCs are
stimulated with the prototypic stimulus bacterial endotoxin
(LPS) in the presence of ATP, profound changes in the
maturation program are induced. While LPS-treated DCs
produce high amounts of proinflammatory (IL-12, IL-23,
TNF-α, IL-1, IL-6) and regulatory (IL-10 and IL-1 receptor
antagonist) cytokines, when stimulated with LPS in the
presence of low concentrations of ATP, DC production of
IL-12, TNF-α, and IL-1 is completely abrogated. Con-
versely, production of the regulatory cytokine IL-10 is
unaffected and IL-1 receptor antagonist is increased. As a
result of the blocked IL-12 production, DCs exposed to
extracellular ATP have reduced ability to induce Th1
differentiation in vitro [62, 63]. In addition, the production
of chemokines preferentially attracting Th 1 polarised
lymphocytes such as CXCL10 and CCL5 is also blocked,
yet DCs still produce high amounts of the Th 2-attracting
chemokines CCL-22 and CCL-17 [56]. The lack of
CXCL10 (a ligand for CXCR3) production might also
impair DC contribution to the recruitment of NK cells into
the lymph node thus further favouring Th 2 development.
Altered DC maturation induced by the presence of
extracellular ATP is reminiscent of the effects of treatment
with cyclic adenosine monophosphate (cAMP)-inducing
agents. Dendritic cells in which intracellular concentration
of cAMP is increased following ligand-activation of Gs
protein-coupled receptors, such as EP2 prostaglandin recep-
tor [64], H2 histamine receptor [65, 66], β-adrenergic
receptors [67], or A2 adenosine receptor [68], display
blocked TNF-α and IL-12p70 production but unaffected or
even increased IL-10 together with augmented expression
Figure 1 (a–c) Proposed role of extracellular ATP in the regulation of
DC trafficking. Due to cell death, the extracellular space surrounding
sites of tissue injury is characterised by increased ATP concentration.
Circulating DCs might follow the ATP gradient to traffic to perile-
sional area where an antigen encounter is more likely to occur (a) and
where ATP might reach concentrations in the micromolar range.
P2Y11 activation transiently inhibits DCs migration, prolonging their
persistence at the site of antigen encounter (b). At later stages, due to
the action of ecto-nucleotidases, extracellular ATP levels drop down,
and the chemokines CCR7 and CXCR4 are upregulated by P2Y11
signaling. This sets DCs for efficient migration from peripheral tissues
toward regional lymph nodes (c).
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increasing intracellular cAMP by ADP ribosylation of the
Gαs subunit of G proteins by cholera toxin [69, 70], by
stimulation of adenylyl cyclases through forskolin admin-
istration [67] and by treatment with membrane-permeable
cAMP analogues such as dibutyryl cAMP [67]o r8 -
bromocyclic AMP [71]. Extracellular ATP can increase
the intracellular level of cAMP through the activation of the
P2Y11 receptor that is coupled to the adenylyl cyclase and
the phosphoinositide pathways [72]. Moreover P2Y11 has
been suggested to be the P2 receptor mediating the ATP-
induced DC maturation [13]. The stimulation of the cAMP
pathway is also involved in the reported synergy between
extracellular ATP and TNF-α or suboptimal doses of LPS
in the induction of IL-12p40 by DCs. Either TNF-α or
suboptimal doses of LPS are unable to elicit IL-12
production unless this stimulation takes place in the
presence of extracellular ATP [13, 73]. However the
synergistic effect is limited to the IL-12 p40 chain; no IL-
12p70 heterodimer is produced by DCs exposed to
extracellular ATP irrespective of the stimulus used [63].
Interestingly, under optimal stimulation conditions, the
concomitant activation of the cAMP pathway by either ex-
tracellular ATP or prostaglandin E2, besides inhibiting
IL-12p70, results in enhanced production of IL-23, a
heterodimeric cytokine, a member of the small IL-12
family, composed of the p19 and IL-12p40 proteins. While
IL-12 p70 is essential for the polarisation of naïve T cells
toward Th 1 phenotype, IL-23 is thought to act preferen-
tially on memory T lymphocytes stimulating IFN-γ
production [74]. Consistently, DCs stimulated with E. coli
in the presence of ATP display decreased ability to prime
Th 1 responses but are still efficient in promoting IFN-γ
production by memory T lymphocytes [75]. This might
have important consequences for the regulation of immune
responses as follows: in the presence of excessive tissue
damage, large amounts of self peptides usually confined
in the intracellular compartment become available to sur-
rounding DCs. These DCs are limited in their ability to
prime Th 1 responses by the concomitant presence of extra-
cellular ATP, thus reducing the risk of activating poten-
tially self-reactive IFN-γ producing cells. Concurrently,
DCs are still able to support IFN-γ production by memory
Tcells, whose priming likely does not occur in the presence
of overwhelming amounts of self-antigens and that therefore
might be instrumental for pathogen eradication.
Triggering the P2Y11 receptor, besides inhibiting Th 1
priming, can also confer immunosuppressive activity to
Figure 2 (a, b) Dendritic cells
shape T lymphocyte responses.
(a) DCs migrating to the lymph
node participate in NK recruit-
ment by producing the CXCR3
ligand CXCL10. NK trafficking
into inflamed lymph nodes is
necessary for efficient priming
of type 1 T lymphocytes. During
antigen presentation, IFN-γ
released by NK allows naïve T
lymphocytes to be activated by
IL-12 through the induction of
IL-12 receptor. Under these
conditions, DCs deliver signal 1
(MHC-peptide complex
engaging TCR), signal 2 (DC
costimulatory molecules CD80
or CD86 engaging CD28 on T
lymphocyte surface) and signal
3 (STAT-4 activation by IL-12).
(b) In ATP-conditioned DCs,
simultaneous inhibition of IL-12
and CXCL10, but not IL-10
production, impairs the
development of type 1
responses: reduced NK
recruitment and antigen
presentation in the absence of
IL-12, but in the presence of
IL-10, favours T helper 2 and/or
T regulatory 1 differentiation.
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showed that extracellular ATP induces DCs to produce
large amounts of thrombospondin-1 (TSP-1) and to express
indoleamine 2,3 dioxygenase [76]. Thrombospondin-1
exerts immunoregulatory activity by different mechanisms:
(1) inhibition of T cell proliferation by binding to its
receptor (CD47) on the cell membrane; (2) autocrine
inhibition of IL-12 production by activating the phosphoi-
nositol 3 kinase pathway in DCs [77]; (3) autocrine
inhibition of DC activation [78]; (4) activation of the potent
immunosuppressive cytokine TGF-β1[ 79]. In addition
Marteau and colleagues showed that ATP synergizes with
IFN-γ to induce the expression of indoleamine 2,3
dioxygenase (IDO) [76]. Dendritic cells expressing IDO,
an intracellular enzyme involved in the catabolism of the
essential amino acid tryptophan, suppress T cell prolifera-
tion and promote tolerance [80–83]. In summary, while
chronic exposure to very low (nanomolar) concentrations of
extracellular ATP induces chemotactic activity of DCs,
micromolar concentrations modify DC function to promote
less self-harmful type 2 responses and/or tolerance by a
variety of mechanisms due to adenylyl cyclase activation.
Another set of studies addressed the effects on DC
physiology of high extracellular ATP doses showing that in
the millimolar range, ATP causes the opening of P2X7 ion
channel across the DC membrane and consequently
increases permeability to low molecular weight solutes.
Due to the availability of specific antibodies and inhibitors,
P2X7 is the best characterised P2 receptor. It is expressed at
very high levels on both murine and human DCs [31, 84].
Enhanced DC membrane permeability following treatment
with ATP doses suggestive of activation of the P2X7 pore
triggers rapid secretion of IL-1β and TNF-α by mature
dendritic cells [31]. It has been shown that in mononuclear
phagocytes, P2X7-mediated IL-1β release is due to the
activation of interleukin-1-converting enzyme/caspase-1,
which cleaves pre-stored IL-1 precursor to produce the
mature form of IL-1β [85]. High membrane expression of
P2X7 by DCs correlates with sensitivity to cytotoxic effects
of extracellular ATP inducing apoptosis or necrosis depend-
ing on the dose and length of exposure [84, 86, 87].
Moreover it has been suggested that during antigen
presentation, macrophages that upon activation have upre-
gulated P2X7 expression might be lysed by ATP released
from cytotoxic T lymphocytes [88]. Inhibition of P2X7
activation by oxidised ATP results in the prevention of
P2X7-induced cell death as well as down-modulation of
LPS-induced signaling. In particular, decreased activation
of nuclear factor-κB, and of extracellular signal-regulated
kinases 1 and 2 are observed in macrophages stimulated
with LPS in the presence of P2X7 antagonist, pointing to a
role of P2X7 signaling in cell activation induced by Toll-
like receptor engagement [89].
Although there is a substantial discrepancy between
physiological ATP levels detected in the extracellular space
and the concentration needed to trigger P2X7 in vitro,i ti s
important to consider that the average extracellular nucle-
otide concentrations might represent significantly different
local distributions. In close proximity to leaking plasma
membranes of damaged cells, as well as of healthy actively
secreting cells, nucleotides might locally reach molar
concentration. Moreover, upon activation of pore-forming
P2X7, the egress of intracellular nucleotides through the
pore can trigger P2X7 on the membrane of adjacent cells,
resulting in the amplification of local release of intracellular
nucleotides in the extracellular milieu. Furthermore, the
microbicidal peptide LL37, representing the C terminus of
the cathelicidin family member cationic peptide 18 pro-
duced by neutrophils and epithelial cells, has been reported
to be an endogenous P2X7 activator that triggers maturation
and release of IL-1β from LPS-primed monocytes [90].
The concentration of ATP needed for P2X7 activation in
vitro might not reflect the physiological situation. For
example, recent evidence provided by Seman and co-
workers showed that P2X7 activation can be triggered by
nicotinamide-adenine dinucleotide (NAD)-dependent puri-
noceptor ADP-ribosylation [91]. Although NAD itself is
not a ligand for P2X7, NAD released upon tissue injury and
inflammation represents the substrate for ecto-ADP ribo-
syltransferase-2 (ART-2) catalyzing ADP-ribosylation of
P2X7. Interestingly, NAD derived from cell lysates is
sufficient to activate P2X7 and in the presence of NAD,
P2X7 activation can be triggered by low ATP concen-
trations. Similarly, we showed that otherwise ineffective
concentrations of ATP induce P2X7-mediated cytotoxicity
in the presence of the antibiotic polymyxin B [92]. These
studies demonstrate that (1) P2X7 and possibly other
purinergic receptors might be activated by non-nucleotide
agonists, and (2) in vivo, different agonists can cooperate
and activate purinoceptors at significantly lower concen-
trations than those needed in vitro.
To date no study has specifically addressed the modu-
lation of dendritic cell activity by extracellular nucleotides
in vivo. However the in vivo administration of the ATP
analogue 2-methylthio-ATP inhibits the release of TNF-α
and IL-1 and protects mice from endotoxin shock [93, 94].
Although these studies did not specifically address the
contribution of DCs to the inflammatory response to LPS,
their results are in keeping with what was observed in
human monocyte-derived DCs stimulated in vitro with LPS
in the presence of extracellular ATP [62, 63].
Mizumoto and colleagues studying contact hypersensi-
tivity to haptens in CD39-deficient mice showed that the
impairment of DC ability to metabolise extracellular
nucleotides significantly influences their function in vitro
and in vivo. CD39
−/− Langerhans cells and bone marrow-
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consequent accumulation of extracellular nucleotides in the
pericellular space. Under these conditions, DCs and Lang-
erhans cells are unresponsive to ATP due to P2 receptor
desensitisation and display impaired antigen-presenting
capacity. Moreover T lymphocytes increase pericellular
ATP concentration upon activation, suggesting that nucleo-
tides have an important role in DC–T cell communication
during antigen presentation [55].
Conclusions
Nucleotides, in particular ATP, have been proposed as
endogenous signals of tissue stress. In addition, ATP actively
secreted by T lymphocytes might work as an important
mediator for cell–cell communication during antigen pre-
sentation. In fact extracellular nucleotides, by stimulating P2
receptors, can profoundly influence DC functions and have a
great impact on the outcome of immune response. Chronic
exposure to low (micromolar) concentrations of extracellular
ATP might work as negative feedback to limit DC
contribution to exacerbated inflammation, mainly through
the activation of P2Y11 and the following rise in the
intracellular cAMP concentration. Concentration gradients
of extracellular ATP attract immature DCs into injured
tissues and prolong their permanence at the site of antigen
encounter. In the proximity of damaged cells, where the
concentration may be in the micromolar range, ATP blocks
the synthesis by DCs of proinflammatory cytokines and
chemokines for the recruitment of NK cells and type 1
polarised T lymphocytes and limits DCs’ capacity to pro-
mote type 1 responses. As a result, the development of less
self-harmful type 2 responses is favoured. In addition, ex-
pression of regulatory molecules such as IDO and throm-
bospondin-1 might turn DCs into active regulatory cells
promoting tolerance rather than immunity.
On the other hand, high concentrations of extracellular
ATP causes DC death through P2X7 activation and might
representamechanismfortheeliminationofantigen-present-
ing cells into the lymph node by activated T lymphocytes.
Although further in vivo studies are required to confirm the
observations made on monocyte DCs in vitro, targeting P2
receptor function might represent a promising approach to
enhance immune responses for increased vaccination efficacy
or conversely, to promote the tolerogenic functions of DCs for
the treatment of inflammatory and autoimmune diseases.
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